Mesa Laboratories (MLAB) Stock Price, News & Analysis

Company Overview

Mesa Laboratories, Inc. develops and manufactures products used for quality control, monitoring, and measurement in healthcare, pharmaceutical, industrial, and other regulated applications. The company’s offerings are designed to help customers verify the performance of processes, equipment, and environmental conditions.

Mesa Laboratories’ product portfolio includes sterilization assurance products, such as biological indicators and related monitoring systems, as well as instruments and consumables used in healthcare and laboratory settings. The company also provides products for monitoring temperature, pressure, humidity, and other critical conditions, along with testing solutions for applications including dialysis and water quality.

Founded in 1979 and headquartered in Lakewood, Colorado, Mesa Laboratories serves customers in the United States and international markets. Its products are used by hospitals, pharmaceutical and medical-device manufacturers, laboratories, and industrial organizations that require reliable measurement and process-verification tools.

Key Stats

• Today's Range: $119.47 to $128.60
• 50-Day Range: $119.30 to $142.23
• 52-Week Range: $69.51 to $144.35
• Volume: 109,672 shs
• Average Volume: 92,333 shs
• Market Capitalization: $717.69 million
• P/E Ratio: 152.68
• Dividend Yield: 0.50%
• Price Target: $110.00
• Consensus Rating: Hold

Mesa Laboratories Stock Analysis - MarketRank™

Mesa Laboratories scored higher than 25% of companies evaluated by MarketBeat, and ranked 774th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Mesa Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and no sell ratings.

Downside Risk

Mesa Laboratories has a consensus price target of $110.00, representing about 14.2% downside from its current price of $128.25.

Amount of Analyst Coverage

Mesa Laboratories has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mesa Laboratories is 152.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.38.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mesa Laboratories is 152.68, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.66.

Price to Book Value per Share Ratio

Mesa Laboratories has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.18% of the float of Mesa Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Mesa Laboratories has a short interest ratio ("days to cover") of 3.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mesa Laboratories has recently decreased by 12.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Mesa Laboratories has a dividend yield of 0.54%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Mesa Laboratories does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Mesa Laboratories is 76.19%. Payout ratios above 75% are not desirable because they may not be sustainable.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Mesa Laboratories this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for MLAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Mesa Laboratories in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $102,321.00 in company stock, which represents 0.0143% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Mesa Laboratories insiders have bought 12.79% more of their company's stock than they have sold. Specifically, they have bought $902,411.00 in company stock and sold $800,090.00 in company stock.

Percentage Held by Insiders

2.80% of the stock of Mesa Laboratories is held by insiders.

Percentage Held by Institutions

90.60% of the stock of Mesa Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Record date for 9/15 Dividend: 8/31/2026
• Ex-Dividend for 9/15 Dividend: 8/31/2026
• Dividend Payable: 9/15/2026
• Today: 11/08/2026
• Next Earnings (Estimated): 11/09/2026
• Record date for 12/15 Dividend: 11/30/2026
• Ex-Dividend for 12/15 Dividend: 11/30/2026
• Dividend Payable: 12/15/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:MLAB
• CIK: 724004
• Web: www.mesalabs.com
• Phone: (303) 987-8000
• Fax: 303-987-8989
• Employees: 717
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Mesa Laboratories: $110.00
• High Price Target: $110.00
• Low Price Target: $110.00
• Potential Upside/Downside: -14.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.84
• Trailing P/E Ratio: 152.68
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $6.71 million
• Net Margins: 1.92%
• Pretax Margin: 3.75%
• Return on Equity: 22.72%
• Return on Assets: 9.82%

Debt

• Debt-to-Equity Ratio: 0.73
• Current Ratio: 1.79
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $249.73 million
• Price / Sales: 2.87
• Cash Flow: $11.78 per share
• Price / Cash Flow: 10.89
• Book Value: $33.71 per share
• Price / Book: 3.80

Miscellaneous

• Outstanding Shares: 5,596,000
• Free Float: 5,439,000
• Market Cap: $717.69 million
• Optionable: Not Optionable
• Beta: 1.08